Literature DB >> 17964785

Reliability of clinical outcome measures in Charcot-Marie-Tooth disease.

A Solari1, M Laurà, E Salsano, D Radice, D Pareyson.   

Abstract

We assessed inter- and intra-rater reliability of outcome measures in Charcot-Marie-Tooth disease (CMT) patients. In 40 CMT patients, we assessed reliability of Overall Neuropathy Limitations Scale (ONLS), 10-m timed walk (T10MW), 9-hole-peg test (9-HPT), maximal voluntary isometric contraction (MVIC) of arm (elbow flexion, hand-grip, and three-point pinch) and leg (knee extension, foot dorsiflexion/plantar flexion). Reliability was substantial for ONLS, excellent for T10MW and 9-HPT. For MVIC, inter and intra-rater reliability was excellent for hand contractions; for leg contractions, intra-rater agreement was moderate to substantial, whereas inter-rater agreement was poor. An ad hoc device was produced to immobilize the foot and MVIC reliability was re-assessed in 26 CMT patients, resulting in excellent inter-rater and intra-rater reliability for foot dorsiflexion, and clear inter-rater improvement for foot plantar flexion. All outcome measures appear adequate for CMT assessment. Use of an immobilization device improves foot MVIC reliability, preventing biased findings in patients with greater strength.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17964785     DOI: 10.1016/j.nmd.2007.09.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  17 in total

Review 1.  New insights into the pathophysiology of pes cavus in Charcot-Marie-Tooth disease type 1A duplication.

Authors:  José Berciano; Elena Gallardo; Antonio García; Ana L Pelayo-Negro; Jon Infante; Onofre Combarros
Journal:  J Neurol       Date:  2011-05-18       Impact factor: 4.849

2.  Evolution of Charcot-Marie-Tooth disease type 1A duplication: a 2-year clinico-electrophysiological and lower-limb muscle MRI longitudinal study.

Authors:  Ana L Pelayo-Negro; Elena Gallardo; Antonio García; Pascual Sánchez-Juan; Jon Infante; José Berciano
Journal:  J Neurol       Date:  2014-01-22       Impact factor: 4.849

3.  Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.

Authors:  Camiel Verhamme; Rob J de Haan; Marinus Vermeulen; Frank Baas; Marianne de Visser; Ivo N van Schaik
Journal:  BMC Med       Date:  2009-11-12       Impact factor: 8.775

4.  Flexor digitorum superficialis opposition tendon transfer improves hand function in children with Charcot-Marie-Tooth disease: case series.

Authors:  T Estilow; S H Kozin; A M Glanzman; J Burns; R S Finkel
Journal:  Neuromuscul Disord       Date:  2012-09-01       Impact factor: 4.296

5.  Reliability of the Charcot-Marie-Tooth functional outcome measure.

Authors:  Paula Bray; Kayla M D Cornett; Timothy Estilow; Davide Pareyson; Riccardo Zuccarino; Mariola Skorupinska; Menelaos Pipis; Janet E Sowden; Steven Scherer; Mary M Reilly; Michael E Shy; David N Herrmann; Joshua Burns; Katy J Eichinger
Journal:  J Peripher Nerv Syst       Date:  2020-08-26       Impact factor: 3.494

6.  Outcome measures for Charcot-Marie-Tooth disease: clinical and neurofunctional assessment in children.

Authors:  Emanuela Pagliano; Isabella Moroni; Giovanni Baranello; Anita Magro; Alessia Marchi; Sara Bulgheroni; Maurizio Ferrarin; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

7.  Reliability of instrumented movement analysis as outcome measure in Charcot-Marie-Tooth disease: results from a multitask locomotor protocol.

Authors:  M Ferrarin; G Bovi; M Rabuffetti; P Mazzoleni; A Montesano; I Moroni; E Pagliano; A Marchi; C Marchesi; E Beghi; D Pareyson
Journal:  Gait Posture       Date:  2011-04-21       Impact factor: 2.840

8.  Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.

Authors:  Davide Pareyson; Mary M Reilly; Angelo Schenone; Gian Maria Fabrizi; Tiziana Cavallaro; Lucio Santoro; Giuseppe Vita; Aldo Quattrone; Luca Padua; Franco Gemignani; Francesco Visioli; Matilde Laurà; Davide Radice; Daniela Calabrese; Richard A C Hughes; Alessandra Solari
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

9.  An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.

Authors:  Shahram Attarian; Jean-Michel Vallat; Laurent Magy; Benoît Funalot; Pierre-Marie Gonnaud; Arnaud Lacour; Yann Péréon; Odile Dubourg; Jean Pouget; Joëlle Micallef; Jérôme Franques; Marie-Noëlle Lefebvre; Karima Ghorab; Mahmoud Al-Moussawi; Vincent Tiffreau; Marguerite Preudhomme; Armelle Magot; Laurène Leclair-Visonneau; Tanya Stojkovic; Laura Bossi; Philippe Lehert; Walter Gilbert; Viviane Bertrand; Jonas Mandel; Aude Milet; Rodolphe Hajj; Lamia Boudiaf; Catherine Scart-Grès; Serguei Nabirotchkin; Mickael Guedj; Ilya Chumakov; Daniel Cohen
Journal:  Orphanet J Rare Dis       Date:  2014-12-18       Impact factor: 4.123

10.  Ankle dorsi- and plantar-flexion torques measured by dynamometry in healthy subjects from 5 to 80 years.

Authors:  Amélie Moraux; Aurélie Canal; Gwenn Ollivier; Isabelle Ledoux; Valérie Doppler; Christine Payan; Jean-Yves Hogrel
Journal:  BMC Musculoskelet Disord       Date:  2013-03-22       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.